The Science of Phosphaturic Hormones: How Excess FGF23 Downregulates Kidney Transporters

Fibroblast growth factor 23 (FGF23) is a hormone primarily produced by bone cells (osteocytes and osteoblasts) that plays a central role in phosphate and vitamin D metabolism. Under normal conditions, FGF23 helps maintain stable blood phosphate levels and supports healthy bone mineralization. However, when FGF23 is overproduced—whether due to genetic disorders, tumors, or chronic kidney disease—its actions can tip the balance toward phosphate wasting, low vitamin D levels, and weakened bones.

Understanding how excess FGF23 downregulates kidney transporters provides insight into rare metabolic bone diseases and common complications of kidney dysfunction. Below, we explore:

1. Normal FGF23 physiology
2. Mechanisms of transporter downregulation
3. Causes and consequences of FGF23 overproduction
4. Clinical presentation and testing
5. Management strategies

---

1. Normal Physiology of FGF23

• Source and regulation

  • Produced by osteocytes/osteoblasts in response to high blood phosphate and active vitamin D (calcitriol).
  • Acts as a negative feedback loop to reduce phosphate retention and vitamin D activation.

• Key kidney targets

  • NaPi-IIa and NaPi-IIc transporters in the renal proximal tubule reabsorb ~80% of filtered phosphate.
  • 1α-hydroxylase enzyme converts inactive vitamin D (25-hydroxyvitamin D) into active calcitriol (1,25-dihydroxyvitamin D).
  • 24-hydroxylase enzyme degrades calcitriol, limiting vitamin D’s effects.

• Receptor complex

  • FGF23 binds to fibroblast growth factor receptors (FGFR1c, FGFR3c, FGFR4) in the presence of the co-receptor α-Klotho, mainly expressed in the kidney.

---

2. Mechanisms of Transporter Downregulation

When FGF23 levels rise above normal, several signaling pathways converge to reduce phosphate reabsorption and vitamin D synthesis:

1. FGFR/Klotho binding
   • FGF23 interacts with FGFR1c–α-Klotho complexes on proximal tubular cells.
2. Activation of intracellular cascades
   • ERK1/2 (extracellular signal–regulated kinase) and PLCγ (phospholipase C gamma) pathways trigger downstream effects.
3. Reduction of NaPi-IIa and NaPi-IIc expression
   • Decreased gene transcription and accelerated internalization/degradation of transporter proteins.
   • Results in lower phosphate reabsorption and increased urinary phosphate excretion (phosphaturia).
4. Modulation of vitamin D metabolism
   • Suppresses 1α-hydroxylase (CYP27B1), cutting back on active vitamin D production.
   • Upregulates 24-hydroxylase (CYP24A1), enhancing calcitriol breakdown.
   • Net effect: lower calcitriol levels, reduced intestinal calcium/phosphate absorption, and potential hypocalcemia.

---

3. Causes and Consequences of FGF23 Overproduction

Primary causes of FGF23 overproduction

• Tumor-induced osteomalacia (TIO)
  • Rare mesenchymal tumors secrete excess FGF23.
  • Often presents in adulthood with bone pain, muscle weakness, and fractures.
• Genetic hypophosphatemic rickets
  • X-linked hypophosphatemia (XLH) and autosomal dominant hypophosphatemic rickets (ADHR) feature mutations leading to elevated FGF23 activity.
• Chronic kidney disease (CKD)
  • Reduced nephron mass impairs phosphate excretion, provoking FGF23 rises as compensation.
  • Chronically high FGF23 may contribute to cardiovascular complications.

Downstream effects of sustained FGF23 excess

• Persistent hypophosphatemia: weakens bone mineralization, leading to rickets in children and osteomalacia in adults.
• Low calcitriol levels: impairs calcium absorption, potentially causing secondary hyperparathyroidism.
• Muscle weakness and bone pain: phosphate is vital for energy metabolism (ATP) and skeletal integrity.
• In CKD, elevated FGF23 associates with left ventricular hypertrophy and increased mortality.

---

4. Clinical Presentation and Testing

Common signs and symptoms

• Bone pain and tenderness
• Muscle weakness or fatigue
• Fractures with minimal trauma
• Skeletal deformities (in children)
• Symptoms of low vitamin D: muscle cramps, paresthesias

Laboratory evaluation

• Serum phosphate: low
• Serum FGF23: elevated (intact FGF23 assays)
• 1,25-dihydroxyvitamin D: low or inappropriately normal
• Parathyroid hormone (PTH): may be elevated secondary to hypocalcemia
• Urinary phosphate excretion: increased fractional excretion

Imaging and localization (in TIO)

• Functional imaging (Octreotide or PET scans) to locate FGF23-secreting tumors.
• Whole-body MRI or CT for anatomical detail.

Feeling unsure about bone pain or muscle weakness? Try a free, online symptom check, using the doctor approved Ubie Symptom Checker to explore possible causes and next steps.

---

5. Management Strategies

Tumor-induced osteomalacia (TIO)

• Tumor removal: surgical resection is often curative, normalizing FGF23 and restoring phosphate balance.
• Medical therapy (if tumor is unresectable):
  • Phosphate supplements (multiple daily doses).
  • Active vitamin D analogs (calcitriol or alfacalcidol) to offset low calcitriol and support bone health.

Genetic hypophosphatemic disorders

• Phosphate and vitamin D: lifelong supplementation tailored to serum levels.
• Burosumab: a monoclonal antibody targeting FGF23, approved for XLH in both pediatric and adult patients. Improves phosphate levels, bone pain, and physical function.

Chronic kidney disease (CKD)

• Dietary phosphate restriction: limit high-phosphate foods.
• Phosphate binders: reduce intestinal phosphate absorption.
• Vitamin D analogs: manage secondary hyperparathyroidism.
• Monitoring FGF23 levels may guide risk assessment for cardiovascular complications.

---

Putting It All Together

Excess FGF23 represents a key driver of phosphate wasting and impaired vitamin D metabolism. By binding to FGFR/Klotho complexes in the kidney, FGF23:

• Downregulates NaPi-IIa and NaPi-IIc transporters
• Suppresses 1α-hydroxylase while enhancing 24-hydroxylase
• Leads to low phosphate, low calcitriol, and weakened bone mineralization

Whether due to rare tumors, inherited conditions, or chronic kidney disease, understanding FGF23 overproduction helps clinicians tailor diagnosis and treatment. Advances such as FGF23-specific antibodies (burosumab) and improved imaging techniques have transformed outcomes for many patients.

If you or someone you know experiences unexplained bone pain, frequent fractures, or muscle weakness, it’s important to get evaluated early. Consider taking a free, online symptom check, using the doctor approved Ubie Symptom Checker to learn more about potential causes. And remember—always speak to a doctor about anything that could be life threatening or serious.